Dataset related to the article "Impact of ventricular tachycardia ablation in subcutaneous implantable cardioverter defibrillator carriers: a multicentre, international analysis from the iSUSI project"

This record contains raw data related to the article "Impact of ventricular tachycardia ablation in subcutaneous implantable cardioverter defibrillator carriers: a multicentre, international analysis from the iSUSI project". Abstract Aims: Catheter ablation (CA) of ventricular tachycardia (VT) has become an important tool to improve clinical outcomes in patients with appropriate transvenous implantable cardioverter defibrillator (ICD) shocks. The aim of our analysis was to test whether VT ablation (VTA) impacts long-term clinical outcomes even in subcutaneous ICD (S-ICD) carriers. Methods and results: International Subcutaneous Implantable Cardioverter Defibrillator (iSUSI) registry patients who experienced either an ICD shock or a hospitalization for monomorphic VT were included in this analysis. Based on an eventual VTA after the index event, patients were divided into VTA+ vs. VTA- cohorts. Primary outcome of the study was the occurrence of a combination of device-related appropriate shocks, monomorphic VTs, and cardiovascular mortality. Secondary outcomes were addressed individually. Among n = 1661 iSUSI patients, n = 211 were included: n = 177 experiencing ICD shocks and n = 34 hospitalized for VT. No significant differences in baseline characteristics were observed. Both the crude and the yearly event rate of the primary outcome (5/59 and 3.8% yearly event rate VTA+ vs. 41/152 and 16.4% yearly event rate in the VTA-; log-rank: P value = 0.0013) and the cardiovascular mortality (1/59 and 0.7% yearly event rate VTA+ vs. 13/152 and 4.7% yearly event rate VTA-; log-rank P = 0.043) were significantly lower in the VTA + cohort. At multivariate analysis, VTA was the only variable remaining associated with a lower incidence of the primary outcome [adjusted hazard ratio 0.262 (0.100-0.681), P = 0.006]. Conclusion: In a real-world registry of S-ICD carriers, the combined study endpoint of arrhythmic events and cardiovascular mortality was lower in the patient cohort undergoing VTA at long-term follow-up. Clinicaltrials.gov identifier: NCT0473876. Trial registration: ClinicalTrials.gov NCT00473876. Keywords: Arrhythmic mortality; Catheter ablation; Defibrillator; Subcutaneous ICD; Ventricular tachycardia. This dataset is not public. It’s available upon reasonable requesto to the [e-mail].本数据集包含与论文"《皮下植入式心律转复除颤器携带者室性心动过速消融的影响：来自iSUSI项目的多中心国际分析》"相关的原始数据。 摘要 研究目的：经静脉植入式心律转复除颤器（transvenous implantable cardioverter defibrillator, ICD）适当放电患者的临床结局改善中，室性心动过速（ventricular tachycardia, VT）导管消融（Catheter ablation, CA）已成为重要手段。本分析旨在探究室性心动过速消融（VT ablation, VTA）是否对皮下植入式心律转复除颤器（subcutaneous ICD, S-ICD）携带者的长期临床结局存在影响。 方法与结果：本分析纳入了国际皮下植入式心律转复除颤器（International Subcutaneous Implantable Cardioverter Defibrillator, iSUSI）登记库中，曾发生ICD放电或因单形性VT住院的患者。根据索引事件发生后是否最终接受VTA，将患者分为VTA+队列与VTA-队列。本研究的主要结局为器械相关适当放电、单形性VT与心血管死亡的复合事件发生情况；次要结局则分别进行评估。在1661例iSUSI登记库患者中，最终纳入211例：其中177例曾发生ICD放电，34例因VT住院。两组患者的基线特征无显著差异。VTA+队列的主要结局粗事件率与年事件率（5/59，年事件率3.8%）均显著低于VTA-队列（41/152，年事件率16.4%；对数秩检验：P=0.0013）；其心血管死亡率（1/59，年事件率0.7%）亦显著低于VTA-队列（13/152，年事件率4.7%；对数秩检验P=0.043）。多变量分析显示，VTA是唯一与主要结局发生率降低独立相关的变量[校正风险比0.262（0.100~0.681），P=0.006]。 结论：在真实世界的S-ICD携带者登记队列中，长期随访期间接受VTA的患者，其心律失常事件与心血管死亡的复合研究终点事件率更低。 ClinicalTrials.gov 登记号：NCT0473876。 试验注册信息：ClinicalTrials.gov 编号NCT00473876。 关键词：心律失常性死亡；导管消融；除颤器；皮下植入式心律转复除颤器；室性心动过速。 本数据集尚未公开，若有合理需求可发送邮件至[e-mail]申请获取。